We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Haiquan Chen

Haiquan Chen MD

Professor of Oncology, Department of Thoracic Surgery, Fudan University Shanghai Cancer Hospital, Shanghai, China

Dr. Haiquan Chen is a Professor of Oncology at the Department of Thoracic Surgery of Fudan University Shanghai Cancer Hospital. His main research themes are identifying therapeutic targets in lung cancer and clarifying the mechanism of treatment resistance and strategies to overcome them. 

Prof. Chen has published over 50 papers on his research interests. His research team has determined the unique oncogenic mutation spectrums of Chinese patients including lung squamous carcinomas, adenosquamous cell carcinomas, and especially adenocarcinomas and never-smoking lung adenocarcinomas.  They were one of the teams that first revealed ROS1 and RET fusion gene in lung cancer, which are currently well-known as targetable biomarkers.  Their current interest is focused on identifying the mechanism of treatment resistance and strategies to overcome them. 

Dr. Chen is an active member of AATS (American Association for Thoracic Surgery). He is also a vice Editor-in-Chief of Journal of Cancer Research and Clinical Oncology that focuses on translational research in oncology.

Recent Contributions to PracticeUpdate:

  1. FGFR1/3 Fusions Define Unique Molecular Subtype of NSCLC